New Delhi: Gland Pharma  On Wednesday announced the launch of Bortezomib for Injection, a cancer therapy medicine.

The drug firm said in a statement that it has introduced the medicine in the United States market through a partner who has been approved by the US Food and Drug Administration (USFDA).

The Hyderabad-based firm claims that its medicine is therapeutically similar to Velcade for Injection from Takeda Pharmaceuticals. Bortezomib for Injection is a chemotherapy drug that is used to treat cancers like multiple myeloma and mantle cell lymphoma.

Velcade has a market size of USD 1,172 million for the 12 months ending March 2022, according to IQVIA.

For the US market, Gland Pharma is manufacturing and supplying this medicine to its partner.

USFDA approves Aurobindo Pharma's generic cancer drug Bortezomib

DCGI asks Bharat Biotech for additional data on its COVID-19 vaccine for Kids

relief! The great news came amid the fourth wave of Corona, INSACOG said this big thing